In a significant—and potentially disruptive—development in transatlantic trade relations, the United States has initiated a Section 301 investigation into Germany’s pharmaceutical pricing system. What may appear at first glance to be a sector-specific dispute is, in reality, a signal of a broader shift in U.S. trade policy: the willingness to use trade enforcement tools to challenge foreign domestic regulatory regimes. This move carries implications far beyond the life sciences sector.